An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic response in an animal model of adjuvant-induced arthritis

Autoimmunity

Volumn 44, Issue 6, 2011, Pages 471-482

  Dominguez, Maria Del Carmen ^a   Lorenzo, Noraylis ^a   Barbera, Ariana ^a   Darrasse Jeze, Guillaume ^b   Hernández, Maria Victoria ^c   Torres, Ana ^c   Hernández, Isabel ^c   Gil, Rafael ^c   Klatzmann, David ^b   Padrón, Gabriel ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Institute of Rheumatology   (Cuba)

Author keywords

APL; HSP60; Regulatory T cells; Rheumatoid arthritis; Tolerance

Indexed keywords

ALTERED PEPTIDE LIGAND 1; ANTIRHEUMATIC AGENT; AUTOANTIGEN; CD4 ANTIGEN; EPITOPE; HEAT SHOCK PROTEIN 60; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL STIMULATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RAT; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SPLEEN; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; ANIMALS; ARTHRITIS, EXPERIMENTAL; CHAPERONIN 60; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNE TOLERANCE; LIGANDS; LYMPHOCYTE ACTIVATION; MALE; MICE; MIDDLE AGED; PEPTIDES; RATS; RATS, INBRED LEW; T-LYMPHOCYTES, REGULATORY;

EID: 80051504289     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2010.550590     Document Type: Article

References (53)

1. Myew-Ling T, Pierre M. The role of T cells in rheumatoid arthritis: New subsets and new targets. Curr Opin Rheumatol 2007;19:284-288.
2. Miossec P. Il-17 and Th17 in Rheumatoid Arthritis. In: Quesmiaux V, Ryffel B, Padova F, editors. Th 17 cells: Role in inflammation and autoimmune disease. Basel: Irkhäuser Verlag; 2009.
3. Nistala K, Wedderburn LR. Th17 and regulatory T cells: Rebalancing pro-and anti-inflammatory forces in autoimmune arthritis. Rheumatology 2009;48:602-606.
4. Sarkar S, Fox DA. Regulatory T cell defects in rheumatoid arthritis. Arthritis Rheum 2007;56:710-713. (Pubitemid 46399416)
5. \+CD25hi T-regulatory cells. Blood 2006;108:253-261. (Pubitemid 43990636)
6. O'Dell JR. Therapeutic strategies for rheumatic arthritis. N Engl J Med 2004;350:2591-2602.
7. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-2179.
8. Kooloos WM, de Jong DJ, Huizinga TWJ, Guchelaar HJ. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discov Today 2007;12:125-131. (Pubitemid 46176662)
9. Welsing PM, Severens JL, Hartman M, van Riel PL, Laan RF. Modeling the 5-years cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and lefluno-mide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum 2004;51:964-973. (Pubitemid 39648190)
10. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheuma¬toid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
11. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007;204(1):33-39. (Pubitemid 46148753)
12. Cohen IR, Young DB. Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today 1991; 12:105-110.
13. Prakken BJ, Roord S, Ronaghy A, Wauben M, Albani S, van Eden W. Heat shock protein 60 and adjuvant arthritis: A model for T cell regulation in human arthritis. Springer Semin Immunopathol 2003;25:47-63. (Pubitemid 37000038)
14. Cohen IR, Quintana FJ, Mimran A. T regs in T cell vaccination: Exploring the regulation of regulation. J Clin Invest 2004;114:1227-1232. (Pubitemid 40385291)
15. van Eden W, van der Zee R, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol 2005;5:318-330. (Pubitemid 40516157)
16. Alberta GA, van der Zee R, Taams LS, van Eden W. A self-Hsp60 peptide acts as a partial agonist inducing expression of B7-2 on mycobacterial hsp60-specific T cells: A possible mechanism for inhibitory T cell regulation of adjuvant arthritis. Int Immmunol 2000;12:1041-1050. (Pubitemid 30601368)
17. Van Eden W, Thole JER, van der Zee R, Noordzij A, Van Embden JDA, Hensen EJ, Cohen IR. Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature 1988;331:171-173. (Pubitemid 18042149)
18. \+ regulatory T cell function via innate TLR2 signaling. J Clin Invest 2006;116:2022-2032. (Pubitemid 44033326)
19. Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, Sacavulli J, Amox D, Roord S, de Kleer I, Bonnin D, Lanza P, Berry C, Massa M, Billetta R, Albani S. Epitope specific immunotherapy induces immune deviation of proinflamma-tory T cells in rheumatoid arthritis. Proc Natl Acad Sci USA 2004;101:4228-4233. (Pubitemid 38405911)
20. Koffeman EC, Genovese M, Amox D, Keogh E, Santana E, Matteson EL, Kavanaugh A, Molitor JA, Schiff MH, Posever JO, Bathon JM, Kivitz AJ, Samodal R, Belardi F, Dennehey C, van den Broek T, van Wijk F, Zhang X, Zieseniss P, Le T, Prakken BA, Cutter GC, Albani S. Epitope-specific immunotherapy of rheumatoid arthritis. Clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheumat 2009;60:3207-3321.
21. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. b-Cell function in new-onset type 1 diabetes and immuno-modulation with a heat-shock protein peptide (DiaPep277): A randomized, double-blind, phase II trial. Lancet 2001;358: 1749-1753. (Pubitemid 33152998)
22. Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, Johnson EB, Motheral T, Putnam A, Crowe PD, Ling N, Boehme SA, Conlon PJ. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, Based on the Immunodominant Type 1 diabetes autoantigen insulin B-Chain (9-23) peptide. Diabetes 2002;51: 2126-2134. (Pubitemid 34729017)
23. \+ regulatory cells. Proc Natl Acad Sci USA 2005;102:10285-10290. (Pubitemid 41023364)
24. Zhao J, Li R, He J, Shi J, Long L, Li Z. Mucosal administration of an altered CII263-272 peptide inhibits collagen-induced arthritis by suppression of Th1/Th17 cells and expansion of regulatory T cells. Rheumatol Int 2008;29:9-16.
25. Katsara M, Deraos G, Tselios T, Matsoukas J, Apostolopoulos V. Design of novel cyclic altered peptide ligands of myelin basic protein MBP83-99 that modulate immune responses in SJL/J mice. J Med Chem 2008;51:3971-3978. (Pubitemid 351956525)
26. De Magistris M. Antigen analog-major complex histocompat-ibility complexes act as antagonist of the T cell receptor. Cell 1992;68:625-634.
27. Evavold BD. Separation of IL-4 production from Th cell proliferation by an altered T cell ligand. Science 1991;252: 1308-1310. (Pubitemid 21917045)
28. Paas-Rozner M, Sela M, Mozes E. A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25-and CTLA-4-expressing CD4\+ T cells. PANAS 2003;100(11):6676-6681. (Pubitemid 36666640)
29. Singh H, Raghava GPS. ProPred: Prediction of HLA-DR binding sites. Bioinformatics 2001;17:1236-1237. (Pubitemid 33735355)
30. Larche M. Peptide immunotherapy. Immunol Allergy Clin North Am 2006;26:321-332. (Pubitemid 44262083)
31. Garrood T, Pitzalis C. Targeting the inflamed synovium: The quest for specificity. Arthritis Rheum 2006;54:1055-1060. (Pubitemid 43672917)
32. Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA, Maillere B, Kay AB, Larché M. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006;36: 465-474.
33. Manzo BA, Sundstedt A, Minaee S, Symonds A, Khalid S, Nicolson K, Li S, Wraith DC, Wang P. Persistent antigenic stimulation alters the transcription program in T cells, resulting in antigenic-specific tolerance. Eur J Immunol 2006;36:1374-1385. (Pubitemid 43942128)
34. van Eden W. Stress proteins as targets for anti-inflammatory therapies. Reviews 2000;5:115-120. (Pubitemid 30122880)
35. Anderton SM, Zee R, Prakken B, Noordzij A, van Eden W. Activation of T cells recognizing self 60-kD heat shock protein can protect against experimental arthritis. J Exp Med 1995; 181:943-952.
36. van Eden W, Tholet JE, Van der Zee R, Noordzij A, Van Embden JD, Hensen EJ, Cohen IR. Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature 1988;331:171-173. (Pubitemid 18042149)
37. Praken AB, Van Eden W, Rijkers GT, Kuis W, Toebes EA, De Graeff-Meeder ER, van der Zee R, Zegers BJ. Auto-reactivity to human heat shock protein 60 predicts disease remission in oligoarticular juvenile rheumatoid arthritis. Arthritis Rheum 1996;39:1826-1832. (Pubitemid 26378573)
38. van Eden W, van der Zee R, Paul AG, Prakken BJ, Wendling U, Anderton SM, Wauben MH. Do heat shock proteins control the balances of T-cells regulation in inflammatory diseases? Immunol Today 1998;19:303-307. (Pubitemid 28322325)
39. van Eden W, Prakken AB, Albani S. Immunological tolerance in the therapy of rheumatoid arthritis. Discov Med 2007;7: 46-50.
40. Roord ST, Zonneveld-Huijssoon E, Le T, Puga G, Koffeman E, Ronaghy A, Ghahramani N, Lanza P, Billetta R, Prakken BJ, Albani S. Modulation of T cell function by combination of epitope specific and low dose anticytokine therapy controls autoimmune arthritis. PLoS ONE 2006;87(Suppl 1):1-9.
41. Tremoulet AH, Albani S. Novel therapies for rheumatoid arthritis. Expert Opin Investig Drugs 2006;15:1427-1441. (Pubitemid 44615290)
42. Hauet-Broere F, Wieten L, Guichelaar T, Berlo S, van der Zee R, van Eden W. Heat shock proteins induce T cell regulation of chronic inflammation. Ann Rheum Dis 2006;65:65-68.
43. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor Foxp3. Immunity 2005; 22:329-341. (Pubitemid 40387475)
44. Von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005;6:338-344. (Pubitemid 41716770)
45. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133:775-787. (Pubitemid 351707693)
46. Ulmansky R, Cohen CJ, Szafer F, Moallem E, Fridlender ZG, Kashi Y, Naparstek Y. Resistance to adjuvant arthritis is due to protective antibodies against heat shock protein surface epitopes and the induction of IL-10 secretion. J Immunol 2002;168:6463-6469. (Pubitemid 34620071)
47. Van Eden W, Van der Zee R, Paul AGA, Prakken BJ, Wendling U, Anderton SM, Wauben M. Do heat shock proteins control the balance of T cell regulation in inflammatory diseases? Immunol Today 1998;19:303-307. (Pubitemid 28322325)
48. Paul AG, van Kooten PJ, van Eden W, van der Zee R. Highly autoproliferative T cells specific for 60-kDa heat shock protein produce IL-4/IL-10 and IFNg and are protective in adjuvant arthritis. J Immunol 2000;165:7270-7277. (Pubitemid 32001206)
49. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344:904-916.
50. Leipe J, Skapenko A, Lipsky PE, Schulze-Koops H. Regulatory T cells in rheumatoid arthritis. Arthritis Res Ther 2005;7:93.
51. \+ regulatory T cells in rheumatoid arthritis: Differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004;50:2775-2785. (Pubitemid 39209514)
52. Zrour SH, Boumiza R, Sakly N, Mannai R, Korbaa W, Younes M, Bejia I, Touzi M, Bergaoui N. The impact of pregnancy on rheumatoid arthritis outcome: The role of maternofetal HLA class II disparity. Joint Bone Spine 2009; 77(1):36-40.
53. Borchers AT, Naguwa SM, Keen CL, Gershwin ME. The implications of autoimmunity and pregnancy. J Autoimmun 2009;34:287-299.